Twist Bioscience Co. (NASDAQ:TWST) Shares Purchased by Renaissance Technologies LLC

Renaissance Technologies LLC raised its stake in Twist Bioscience Co. (NASDAQ:TWST - Free Report) by 86.0% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 398,708 shares of the company's stock after purchasing an additional 184,398 shares during the quarter. Renaissance Technologies LLC owned about 0.67% of Twist Bioscience worth $18,528,000 at the end of the most recent quarter.

Several other institutional investors also recently made changes to their positions in the stock. Arizona State Retirement System boosted its holdings in Twist Bioscience by 1.3% in the fourth quarter. Arizona State Retirement System now owns 16,985 shares of the company's stock valued at $789,000 after acquiring an additional 219 shares during the last quarter. Van ECK Associates Corp raised its holdings in shares of Twist Bioscience by 56.4% in the 4th quarter. Van ECK Associates Corp now owns 740 shares of the company's stock worth $34,000 after purchasing an additional 267 shares during the period. Hillsdale Investment Management Inc. lifted its stake in shares of Twist Bioscience by 0.4% in the 4th quarter. Hillsdale Investment Management Inc. now owns 78,000 shares of the company's stock valued at $3,625,000 after purchasing an additional 300 shares in the last quarter. US Bancorp DE grew its holdings in shares of Twist Bioscience by 72.0% during the 4th quarter. US Bancorp DE now owns 1,436 shares of the company's stock worth $67,000 after purchasing an additional 601 shares during the period. Finally, Stifel Financial Corp increased its position in Twist Bioscience by 11.8% during the 3rd quarter. Stifel Financial Corp now owns 6,967 shares of the company's stock worth $315,000 after purchasing an additional 734 shares in the last quarter.

Insider Buying and Selling at Twist Bioscience

In other news, insider Dennis Cho sold 806 shares of the stock in a transaction that occurred on Monday, February 3rd. The stock was sold at an average price of $49.35, for a total transaction of $39,776.10. Following the sale, the insider now directly owns 112,221 shares in the company, valued at approximately $5,538,106.35. This represents a 0.71 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, COO Patrick John Finn sold 2,422 shares of the firm's stock in a transaction on Thursday, January 23rd. The shares were sold at an average price of $50.17, for a total value of $121,511.74. Following the completion of the sale, the chief operating officer now owns 272,044 shares in the company, valued at $13,648,447.48. The trade was a 0.88 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 22,796 shares of company stock worth $1,077,383 over the last quarter. 3.01% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several research firms have issued reports on TWST. Barclays decreased their price objective on shares of Twist Bioscience from $58.00 to $45.00 and set an "overweight" rating for the company in a research note on Thursday. Robert W. Baird boosted their price objective on Twist Bioscience from $48.00 to $54.00 and gave the stock an "outperform" rating in a research note on Tuesday, February 4th. Scotiabank reissued an "outperform" rating on shares of Twist Bioscience in a research report on Tuesday, February 4th. Guggenheim set a $50.00 price objective on shares of Twist Bioscience in a research report on Friday, March 28th. Finally, JPMorgan Chase & Co. lifted their price objective on shares of Twist Bioscience from $35.00 to $40.00 and gave the company an "underweight" rating in a research note on Tuesday, February 4th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have given a buy rating to the company's stock. According to MarketBeat.com, Twist Bioscience presently has an average rating of "Moderate Buy" and a consensus target price of $52.80.

Remove Ads

Twist Bioscience Stock Performance

Twist Bioscience stock opened at $38.85 on Monday. The company has a current ratio of 4.96, a quick ratio of 4.62 and a debt-to-equity ratio of 0.03. The stock has a 50 day moving average of $41.83 and a 200-day moving average of $44.65. The stock has a market cap of $2.32 billion, a P/E ratio of -11.49 and a beta of 2.34. Twist Bioscience Co. has a 52 week low of $27.41 and a 52 week high of $60.90.

Twist Bioscience (NASDAQ:TWST - Get Free Report) last announced its quarterly earnings data on Monday, February 3rd. The company reported ($0.53) earnings per share for the quarter, topping the consensus estimate of ($0.62) by $0.09. The company had revenue of $88.70 million during the quarter, compared to analyst estimates of $86.96 million. Twist Bioscience had a negative net margin of 59.76% and a negative return on equity of 32.69%. The firm's revenue for the quarter was up 24.1% compared to the same quarter last year. During the same period last year, the business earned ($0.75) EPS. On average, analysts expect that Twist Bioscience Co. will post -2.12 EPS for the current fiscal year.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.

Want to see what other hedge funds are holding TWST? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Twist Bioscience Co. (NASDAQ:TWST - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.